1 Respiratory Epidemiology and Clinical Research Unit, Centre for Outcomes Research and Evaluation, Research Institute of the McGill University Health Centre, Montreal, QC, Canada. jonathon.campbell@mcgill.ca.
2 Department of Medicine, McGill University, Montreal, QC, Canada. jonathon.campbell@mcgill.ca.
3 Department of Global and Public Health, School of Population and Global Health, Faculty of Medicine and Health Sciences, McGill University, Montreal, QC, Canada. jonathon.campbell@mcgill.ca.
4 Department of Epidemiology, Biostatistics, and Occupational Health, School of Population and Global Health, McGill University, Montreal, QC, Canada.
5 Department of Bioengineering, McGill University, Montreal, QC, Canada.
6 Methodological and Implementation Research Program, The Ottawa Hospital Research Institute, Ottawa, ON, Canada.
7 Lunenfeld-Tanenbaum Research Institute, Sinai Health, Toronto, ON, Canada.
8 Department of Global and Public Health, School of Population and Global Health, Faculty of Medicine and Health Sciences, McGill University, Montreal, QC, Canada.
9 Office of Vice-President, Research, Innovation and Impact, Concordia University, Montreal, QC, Canada.
10 Health Systems & Policy Research Collaborative Centre, University Health Network, Toronto, ON, Canada.

The Government of Canada, through the COVID-19 Immunity Task Force (CITF), supported over 100 serosurveillance studies during the COVID-19 pandemic, building and strengthening the technical infrastructure necessary for a national serosurveillance network. The value of such a network extends beyond infectious disease surveillance to monitoring non-communicable diseases and chemical and environmental contaminants, advancing immunology and medicine, and contributing to national and international research and training. A serosurveillance network can contribute to skill development and retention of the health workforce and provide a platform to rapidly evaluate diagnostics for emerging pathogens. Although full linkage of health data across jurisdictions remains a challenge for such a serosurveillance network to realize its full potential, there are several value streams that make it a worthwhile goal to pursue: improving population health, supporting policy decisions, and facilitating research and diagnostic development. In the aftermath of the COVID-19 pandemic, an integrated pan-Canadian serosurveillance network is a crucial asset going forward.